147 results about "Galactosidases" patented technology

The invention relates to the technical field of prebiotics preparation, and discloses a preparation method of prebiotics applied to reproduced areca catechu, and the preparation method comprises the following steps: carrying out enzyme catalysis reaction on sucrose by adopting fructosyl transferase to prepare fructo-oligosaccharide; according to the method, beta-galactosidase is adopted to carry out enzyme catalysis reaction on lactose, so that galactooligosaccharide is prepared; respectively carrying out decoloration, ion exchange, nanofiltration concentration and spray drying on the candy oligosaccharide and the galactooligosaccharide to obtain powder; the method comprises the following steps: mixing fructo-oligosaccharide powder and galactooligosaccharide powder according to a ratio, and uniformly distributing the mixture in a reproduced areca-nut matrix by adopting a spray-drying blending or low-temperature vacuum mixing mode to form a functional reproduced areca-nut product; according to the invention, low-temperature drying is carried out on the product after blending or vacuum mixing, so that the prebiotic areca nuts are released along with saliva in the chewing process, and are selectively utilized by bifidobacteria and lactic acid bacteria after entering the stomach and intestine, thereby achieving the purposes of regulating intestinal flora and improving the health-care function.

The invention relates to a serum-free culture medium for culturing mesenchymal stem cells as well as a preparation method and application of the serum-free culture medium. Wherein the serum-free culture medium comprises a complete culture medium and praeruptorin E, and the content of the praeruptorin E in the serum-free culture medium is 0.25-3 [mu] M. The inventor finds that a serum-free culture medium containing a certain concentration of praeruptorin E can effectively improve the decline of replicative activity of mesenchymal stem cells in in-vitro passage. Specifically, the serum-free culture medium containing the praeruptorin E with a certain concentration can reduce the expression level of a marker beta-galactosidase with reduced replicative activity in the mesenchymal stem cells with reduced replicative activity after multiple in-vitro passage, reduce the expression of a gene CDKN1A with reduced replicative activity, and increase the multiplication capacity of the mesenchymal stem cells; the mitochondrial damage is reduced.

The invention relates to a chemiluminescence kit for detecting pepsinogen II. The kit comprises an enzyme marker, a luminescent substrate solution and an anti-interference buffer system, the anti-interference buffer system comprises a nonionic surfactant, animal-derived IgG (immunoglobulin G), an antioxidant and catalase; the chemiluminescence kit also comprises a PG II calibration product and a PG II quality control product. The core active component of the enzyme marker is beta-galactosidase. The enzyme marker further comprises an anti-PG II monoclonal antibody marked by beta-galactosidase, bovine serum albumin, trehalose, cane sugar, MgCl2. 6H2O, sodium chloride, Proclin300 and a phosphate buffer solution. According to the kit, a brand-new anti-interference buffer system is introduced on the basis of a spatial proximity chemiluminescence analysis method, so that the resistance to clinically common interferents (such as hemolysis, lipemia, jaundice and heterotropism antibodies) is remarkably improved, and the detection result is more accurate and reliable.

The invention relates to a beta-galactosidase mutant with improved thermal stability and pH stability, and belongs to the technical field of enzyme engineering. The beta-galactosidase derived from Kluyveromyces lactis is subjected to molecular modification, a potential mutation site is determined by using an alanine scanning strategy, beta-galactosidase mutants Pro433Ala and Asp441Ala of which the thermal stability and the pH stability are simultaneously improved are obtained through site-directed mutagenesis screening, the catalytic efficiency of the mutants is improved to 1.03-1.18 times compared with that of the mutants before optimization, and the beta-galactosidase mutant can be used for preparing beta-galactosidase. Wherein the maximum half-life period of the mutant Asp441Ala under the condition of 50 DEG C reaches 91.5 minutes and is increased by 213.4% compared with that of a wild type, the problems of poor catalytic thermal stability and poor pH stability of beta-galactosidase in the prior art are solved, and a brand-new tool is provided for obtaining galactooligosaccharide by using beta-galactosidase to hydrolyze lactose.

Described herein are novel engineered peptides, viral vectors, and pharmaceutical compositions thereof, and uses of the same for increasing α-GAL A expression and for the treatment of conditions associated with α-GAL A deficiency, such as Fabry disease.

The invention relates to a preparation method and application of erythritol galactoside. The method specifically comprises the following steps: constructing a reaction system which takes o-nitrobenzene-beta-D-galactopyranoside as a glycosyl donor, erythritol as a receptor and recombinant beta-galactosidase Bga7 as a catalytic enzyme, so as to prepare the erythritol-beta-galactoside. Wherein the amino acid sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.2, and the nucleotide sequence of the beta-galactosidase Bga7 is as shown in SEQ ID No.1. The invention also provides an application of the erythritol-beta-galactoside in preparation of daily chemical products or medical preparations for resisting streptococcus mutans infection. The invention provides a novel beta-galactosidase Bga7 gene of a glycosidase family 2, and a novel tool enzyme is provided for synthesis of galactoside products. The erythritol-beta-galactoside prepared by the invention has good effects of preventing streptococcus mutans infection and caries, and can be used for preparing daily chemical products or medical preparations for preventing streptococcus mutans infection.

A composition including a gene therapy delivery system and an alpha-galactosidase (GLA) polynucleotide encoding a GLA polypeptide, wherein the GLA polypeptide has at least 95% sequence identity to one of SEQ ID NOS. 1-40, 44-45, 51-52, 57, 61-173 or 212. Also provided are compositions, formulations, fusion proteins, and methods for the treatment of Fabry disease.

This invention provides a method for screening β-galactosidase inhibitors, belonging to the field of pharmaceutical technology. The first step of this method uses fluorescence sensing technology to rapidly identify natural products with β-Gal inhibitory activity. The principle is based on the fluorescence quenching property of p-nitrophenol (PNP) on sulfur quantum dots (SQDs); β-Gal catalyzes the hydrolysis of p-nitrophenyl-β-D-galactopyranoside (PNPG) to generate the specific product PNP; in the presence of β-Gal, PNPG can be enzymatically catalyzed to generate PNP, quenching the fluorescence of SQDs; when screened for β-Gal inhibitory activity, the fluorescence of SQDs can be restored. The second step uses affinity chromatography to capture components in samples with β-Gal inhibitory activity. This method involves immobilizing β-Gal on a support material, eluting with a solvent to obtain components that can bind to β-Gal, and then using liquid chromatography-mass spectrometry (LC-MS) to identify the components. This method can rapidly and accurately screen β-Gal inhibitors from natural products.

The invention provides a near-infrared beta-galactosidase fluorescent probe as well as preparation and application thereof, and relates to the technical field of fluorescent probes, according to the near-infrared beta-galactosidase fluorescent probe, when beta-galactosidase exists, a D-galactosyl group can be split, meanwhile, self-elimination of p-hydroxybenzyl is removed, a fluorescent signal unit is released, and the beta-galactosidase can be detected by the near-infrared beta-galactosidase fluorescent probe. The fluorescence signal is obviously enhanced. Excitation and emission spectra of the near-infrared beta-galactosidase fluorescent probe are both in a near-infrared region, the fluorescence intensity at 760 nm is rapidly increased, the fluorescence intensity rapidly reaches a stable state after 30 min, and compared with a visible light probe, the near-infrared beta-galactosidase fluorescent probe has deeper tissue penetrating capacity, background interference can be effectively avoided, and the resolution ratio is improved; the compound can be applied to beta-galactosidase detection imaging and preparation of beta-galactosidase detection imaging reagents, especially breast cancer detection reagents.

The application discloses a lactobacillus crispatus based on multiple targets to realize anti-aging effect and application of transformation of glycyrrhiza for efficiency enhancement, and belongs to the technical field of microorganisms and the technical field of medicine. The lactobacillus crispatus CCFM1362 provided in the application can ferment glycyrrhiza extract, can improve the content of glycyrrhizic acid, hemiglycyrrhizin isoflavone B, naringenin chalcone and other substances, can enhance the efficacy of glycyrrhiza extract, and can realize the effect of multiple targets for anti-aging, and the specific embodiments are as follows: (1) the content of beta-galactosidase in liver tissue is inhibited; (2) the level of aging-related secretory phenotype in liver tissue is reduced; (3) the Nrf2 related pathway is activated, and the level of oxidative stress is reduced; (4) the NF-kappa B related pathway is activated, and the level of chronic inflammation is reduced. Therefore, the lactobacillus crispatus CCFM1362 and the glycyrrhiza extract have great application prospect in the production of anti-aging products.

The invention belongs to the technical field of natural pigments, and particularly relates to a method for improving the performance of blueberry anthocyanin by using tamarind polysaccharide. According to the method for improving the performance of the blueberry anthocyanin by utilizing the tamarind polysaccharide, after a tamarind polysaccharide solution and a blueberry anthocyanin solution are prepared, the tamarind polysaccharide which is not subjected to enzymolysis or the tamarind polysaccharide which is subjected to enzyme treatment such as beta-galactosidase and the like is added into the blueberry anthocyanin solution for mixing; a blueberry anthocyanin stable solution is obtained; blueberry anthocyanin and tamarind polysaccharide in the blueberry anthocyanin stabilizing solution are compounded through non-covalent bonds such as hydrogen bonds, so that the stability of the blueberry anthocyanin in light, heat and digestive systems is improved, the oxidation resistance is enhanced, and the color is improved; therefore, the technical problem that the performance of the blueberry anthocyanin is easily reduced at present is solved.

Levels of expression of antibiotic resistance genes are increased up to six-fold by inserting a proteasome-targeting tag into transgenes expressed in eukaryotic cells. Various selectable marker proteins are combined with different destabilization domains, leading to up to 70% increase in transgene expression. The increase in expression varies highly depending on the engineered construct and the lines cells used. Increase in expression drives exosome loading of cargo proteins in some aspects. By increasing expression and by editing trafficking signals of cargo proteins, proteins that normally locate to the ER can be trafficked to exosomes. This disclosure discloses efficient exosome delivery of a wide variety of engineered proteins, including modified antigen proteins of SARS-CoV-2 and influenza, and other proteins such as a modified alpha galactosidase A, an extracellular domain of vascular endothelial growth factor fused to a constant region of a human immunoglobulin heavy chain, and modified trastuzumab heavy and light chains.

The invention relates to a polynucleotide comprising a lacZ gene (lacZFS) encoding a β-galactosidase characterized by a particular profile with respect to its lactose hydrolysis efficiency. The invention also relates to a strain of Streptococcus thermophilus comprising a lacZFS allele and a bacterial composition thereof, and its use for obtaining fermented milk that does not undergo subsequent acidification.

The invention relates to the technical field of traditional Chinese medicine compositions, and provides a traditional Chinese medicine composition for removing acnes, which is prepared from the following components in parts by weight: 1-2 parts of honeysuckle stem extract, 0.3-0.8 part of fructus forsythiae extract, 2-4 parts of radix scutellariae extract, 0.5-3.5 parts of cortex magnoliae officinalis extract and 1-5 parts of astragalus complanatus extract. The preparation method of the fructus forsythiae extract comprises the following steps: crushing fructus forsythiae, performing steam explosion treatment to obtain pretreated fructus forsythiae, adding water, adding biological compound enzyme, performing enzymolysis, filtering and performing enzyme deactivation to obtain filtrate; enabling the filtrate to pass through macroporous resin, washing with water, carrying out first elution to obtain a solution I, and carrying out second elution to obtain a solution II; performing post-treatment on the solution I to obtain forsythiaside; performing post-treatment on the solution II to obtain forsythin; the biological compound enzyme comprises alpha-galactosidase, lipase and xylanase. Through the technical scheme, the problem of low extraction rate of forsythin and forsythiaside in fructus forsythiae in the prior art is solved.

The application provides an application of scEMC10 in treatment and diagnosis of brain vascular endothelial cell aging, and relates to the technical field of biomedicine. The inventor finds that scEMC10 deficiency leads to brain microvascular endothelial cell aging; brain microvascular endothelial cells treated by scEMC10 can down-regulate beta-galactosidase, SASP and classic aging markers related to aging; after old mice and 5XFAD model mice of Alzheimer's disease are supplemented with scEmc10, the movement coordination ability and spatial cognitive ability of the mice can be obviously improved, and the relative content of the Parkinson's disease marker, phosphorylated alpha-synuclein, of the old mice can be obviously reduced, and the content of the tyrosine hydroxylase phosphorylation activity form can be increased. Therefore, scEMC10 can be used for treatment of brain microvascular endothelial cell aging, improvement of Alzheimer's disease and Parkinson's disease, and detection of brain microvascular endothelial cell aging as a marker.

The invention provides a beta-galactosidase compound and a method. The beta-galactosidase compound comprises beta-galactosidase and cyclic adenosine monophosphate combined with amino acid residues of the beta-galactosidase. According to the invention, small molecular cyclic adenosine monophosphate acts on lactase molecules, and the catalytic activity of lactase is significantly enhanced through unique intermolecular interaction. Compared with a traditional lifting means, the method has the advantages that the lifting efficiency is higher, an ideal lactase activity level can be achieved in a shorter time, and a powerful guarantee is provided for lactose digestion and utilization.

The invention relates to the technical field of gene engineering and protein modification, in particular to an alpha-galactosidase mutant and application thereof. On the basis of alpha-galactosidase AG2, the invention provides at least one protein which is selected from S41H, I108V, S146M, A174W, A176M, N201Y, V202P, K206Y, V211W, A230L, D233S, S239H, A268I, V328I, T347K, T347L, T347Q, H358E, T395K, T395R, V397M, N407A, A459C, A462D, A462Q, T478K, N487L, Q502C, Q539M, Q539Y, A552P, A577S, compared with a wild type, the heat resistance of the mutant is remarkably improved, and wide application of the mutant in feed is facilitated.

The invention discloses application of a targeted stimulating molecule in preparation of drugs, health care products and cosmetics for preventing and treating natural aging, and relates to the field of biological medicines. The molecule provided by the invention can mediate the interaction between senescence cells and immune cells, enhance the endogenous immune function, and achieve the purposes of effectively removing senescence cells and improving senescence-related diseases. One end of the functional molecule for targeted senescence cell immune sensitization targets senescence cell membrane molecules, glutamic acid is marked on the surfaces of senescence cells, coupling between endogenous immune cells and the senescence cells is mediated, and adhesion and removal of the senescence cells by the immune cells are promoted. The molecule can regulate the immune microenvironment of senescent tissues, effectively reduce the number of positive senescent cells of senescence-related beta-galactosidase, improve the natural senescence phenotype of an organism and recover the phenotype and function of senescent skin.

A method for producing a secreted β-galactosidase, characterized by integrating a non-secreted β-galactosidase gene derived from a basidiomycetous yeast into Aspergillus oryzae to produce a secreted β-galactosidase, and a method for producing a galactooligosaccharide using a β-galactosidase produced by the method facilitate the production of a galactooligosaccharide.

The application discloses a beta-galactosidase near-infrared fluorescent probe with a large stokes shift and a preparation method and application thereof. The structure of CPD-gal is shown in formula I. When a 580nm excitation wavelength is used for excitation, CPD-gal has weak fluorescence at 713nm, but can selectively undergo a fluorescence opening reaction with beta-gal. With the increase of the concentration of beta-gal, the fluorescence intensity at 713nm is gradually enhanced, and other interfering ions and species will not interfere with the detection of beta-gal by CPD-gal. Since the emission wavelength is in the near-infrared region and a large stokes shift is generated, the system background fluorescence interference is greatly reduced, and the sensitivity of the detection of beta-gal is improved. Therefore, CPD-gal is suitable for the fluorescence detection of beta-gal with high selectivity and high sensitivity. The probe is successfully applied to the fluorescence imaging of endogenous beta-gal in HeLa cells and SK-OV-3 cells.

The invention provides a preparation method of a double-layer functionalized PS / GO nanofiber membrane, which can realize co-immobilization of yeast and beta-galactosidase, and belongs to the technical field of material chemistry and food biology. According to the method, beta-galactosidase and saccharomyces cerevisiae are successfully fixed on a functionalized graphene oxide modified double-layer polystyrene nanofiber membrane through a packaging method and an adsorption method, monosaccharide-free galactooligosaccharide (GOS) is obtained in one step by taking lactose as a raw material, and a novel biological catalysis system integrating GOS biosynthesis and monosaccharide removal is successfully constructed. In the catalytic system, the hydrolysis activity of the immobilized beta-galactosidase and the transglycosidase activity are remarkably improved compared with free enzymes, and the synthesis efficiency of GOS is effectively improved through the high transglycosidase activity of the immobilized beta-galactosidase. After being treated by the immobilized yeast cells, the yield of the GOS is still kept at a relatively high level of 56%, and more than 90% of monosaccharide in the product is consumed by the yeast cells, so that the high-purity GOS is obtained. And the catalytic system can be repeatedly used for multiple times, and the beta-galactosidase still keeps the enzyme activity of 50% or more after being recycled for 20 times, so that the preparation and production cost of the GOS can be effectively reduced. According to the preparation method of the double-layer functionalized PS / GO nanofiber membrane and the co-immobilization method of the yeast and the beta-galactosidase, provided by the invention, high-efficiency and low-cost preparation of high-purity GOS can be realized.

The application discloses a beta-galactoside enzyme mutant and application thereof. The application takes wild-type beta-galactoside enzyme Bgal1-3 as a parent to provide a mutant with improved thermal stability, enzyme activity and / or oligogalactose production capacity compared with the parent. Meanwhile, the application takes the mutant M9 of Bgal1-3 as a parent to provide a mutant with improved hydrolysis activity compared with the parent. The beta-galactoside enzyme mutant can be used for converting lactose to produce low / zero-lactose or oligogalactose-rich dairy products, and is beneficial to the development of low / zero-lactose or oligogalactose-rich dairy product related industry.

Disclosed are use of a circRNA molecule as a diagnostic marker in a cell senescence diagnosis kit, and use thereof as a treatment target for cell senescence. The present invention finds that circHERC1 is lowly expressed in both cell models of natural senescence and induced senescence. Overexpression of circHERC1 in endothelial cells can improve the proliferation capacity of the endothelial cells, effectively extend the telomere length of the cells, activate telomerase, reduce the β-galactosidase positive rate of the cells, and reduce the expression of all senescence-associated proteins. Introduction of exogenous circHERC1 into mice can effectively delay the senescence of various organs and the shortening of telomeres in aged mice and reduce the β-galactosidase positive rates of various organs of aged mice.

The present invention relates to a food ingredient comprising galactooligosaccharides and nutrients, a way of producing it and beverage products comprising the ingredient. The food ingredient is produced by adding a beta-galactosidase to a composition comprising non-fat milk solids including lactose. The food ingredient may be used e.g. in beverage products to reduce fat and / or sugar without detrimentally impacting sweetness, taste and / or texture. The invention further relates to methods and compositions for treating and / or preventing gastrointestinal disorders and / or improving digestive comfort in a pregnant or lactating individual in need thereof, the composition comprising a low sugar, low lactose, milk-based composition comprising galactooligosaccharide (GOS).

The invention relates to the technical field of gene engineering and protein modification, in particular to a heat-resistant alpha-galactosidase mutant. On the basis of alpha-galactosidase AG2, the invention provides at least one protein which is selected from S41H, I108V, S146M, A174W, A176M, N201Y, V202P, K206Y, V211W, A230L, D233S, S239H, A268I, V328I, T347K, T347L, T347Q, H358E, T395K, T395R, V397M, N407A, A459C, A462D, A462Q, T478K, N487L, Q502C, Q539M, Q539Y, A552P, A577S, compared with a wild type, the heat resistance of the mutant is remarkably improved, and wide application of the mutant in feed is facilitated.

This invention discloses *Bifidobacterium longum* with anti-aging functions and its applications, belonging to the field of microbial technology. The *Bifidobacterium longum* BBS 02 provided by this invention can promote cell vitality and proliferation, inhibit the high activity of β-galactosidase in senescent cells, and inhibit the high expression of the cyclin-dependent kinase inhibitor gene Cdkn1a, thereby achieving an anti-aging effect. The *Bifidobacterium longum* BBS 02 can be used to prepare edible nutrients or skin nutrients.

The invention relates to the technical field of traditional Chinese medicine compositions and cosmetics, and discloses an anti-aging traditional Chinese medicine compound composition which is prepared from cistanche, radix achyranthis bidentatae, eucommia ulmoides, dendrobium flowers, polygala tenuifolia, roses, Chinese yam, angelica sinensis, salvia miltiorrhiza and liquorice. The traditional Chinese medicine compound composition prepared by the method can significantly inhibit the activity of an intracellular senescence marker beta-galactosidase and the expression of P16 or P21, improve the oxidation resistance of cells, improve the spatial learning and memory ability of senescent mice and recover the cardiac ejection ability of mice, exert a significant anti-senescence effect, and has good application prospects. The method has great popularization and application values.

Aspects of the disclosure relate to compositions and methods for the treatment of lysosomal storage disorders, such as GM1 gangliosidosis, Tay Sachs disease, and Sandhoff disease. In some embodiments, the compositions comprise viral vectors encoding beta-galactosidase. In some embodiments, the compositions comprise viral vectors encoding beta-hexosaminidase subunits (e.g. HEXA, HEXB, or combinations thereof).

The invention provides an application of a lipid peroxidation inhibitor in preparation of an anti-premature senescence syndrome drug or an anti-aging drug. Experiments prove that by adding the lipid peroxidation inhibitor, the cell nucleus morphology of cells can be effectively maintained, the expression of intracellular senescence-related beta-galactosidase is reduced, the senescence characteristic of the cells is delayed, and nuclear membranes and nuclear fiber layers damaged due to Progyrin accumulation are repaired, so that the normal functions of the cell nucleuses are recovered, the activity and functions of the cells are improved, and the anti-aging effect is achieved. Powerful cellular level support is provided for relieving and treating the early senescence syndrome and senescence.

The invention relates to a lyophilized preparation containing alpha-galactosidase A fusion protein and a preparation method of the lyophilized preparation.